WONCA研究论文摘要汇编--安大略省初级保健癌症筛查成本激励效应.pdfVIP

3540 · · 2014 NCCN Guideline Updates：Experts Highlight New Recommendations for Clinical Practice At the recent National Comprehensive Cancer Network NC- aged 70 years or for patients who are diagnosed later in life （ ， ， CN 19th Annual Conference experts discussed this year s up- when ≤they meet the Bethesda Guidelines. ） ， dates to the NCCN Clinical Practice Guidelines in Oncology. The Bevacizumab Avastin has been added as an option in combi- · （ ） ， meeting also included reviews of NCCN Task Force reports on issues nation with FOLFOXIRI as an initial therapy for advanced or me- ， in supportive care. We asked eleven NCCN panel members to select tastatic disease or for unresectable synchronous liver and / or lung the most significant updates and insights presented at the confer- metastases. ence. Regorafenib Stivarga which had been recommended only for · （ ）， Al B. Benson III MD Robert H. Lurie Comprehensive Canc- KRAS mutant tumors is now a treatment option for all patients who ， （ ， er Center of Northwestern University 寓寓寓寓寓寓寓寓寓寓寓寓 This years updates contain have progressed through all available regimens eg KRAS mutant ） （ ， small but significant changes on several fronts - everything from the or KRAS wild - t